期刊文献+

胰岛素分泌高峰延迟的2型糖尿病患者应用预混人胰岛素出现餐后低血糖调整治疗案例分析 被引量:1

下载PDF
导出
摘要 目的:研究胰岛素分泌高峰延迟的2型糖尿病患者应用预混人胰岛素后,在空腹及餐后2小时血糖基本达标时出现餐后低血糖,调整不同治疗方案,以寻求临床安全有效的解决途径。方法:选择89例应用预混人胰岛素的2型糖尿病患者,均符合胰岛素分泌高峰延迟且空腹及餐后2小时血糖基本达标,但在进餐后3~5小时均出现低血糖情况,将其分成4组,即A组19例,给予低血糖对症治疗而未调整治疗方案;B组24例,加用拜唐平;C组25例,将混人胰岛素调整为诺和锐30;D组21例,采用分餐方法。观察各组在空腹及餐后2小时血糖无明显改变的情况下,应用CGMS对其进行72小时血糖监测,其间监测指端血糖谱并输入CGMS以校正,根据血糖监测图谱观察各组空腹及餐后2小时、4小时血糖水平、低血糖发生次数、餐后血糖波动幅度(PPGE)、日最大血糖波动幅度(LAGE)。结果:各组的空腹及餐后2小时血糖均无显著差异;B组、C组及D组的进餐4小时血糖均较A组有所上升,低血糖发生次数则显著下降(P<0.05),B在及C组间无差异,和D组比较均有显著差异(P<0.05);餐后血糖波动幅度(PPGE)、日最大血糖波动幅度(LAGE)B组、C组及D组较A组有所下降,B组下降较为显著(P<0.05)。结论:知道患者加餐、加用拜唐平及调整剂型为诺和锐30,对纠正其餐后低血糖均有较好的疗效,加用拜唐平或调整剂型为诺和锐30的方法效果更佳。而应用拜唐平还可以有效地减少血糖波动,平稳控制血糖。
作者 谭普力
出处 《中国社区医师(医学专业)》 2013年第7期138-138,共1页
  • 相关文献

二级参考文献10

  • 1Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care, 2003,26: 1685-1690.
  • 2Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med, 1988,318 : 1231-1239.
  • 3Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA ( 1C ). Diabetes Care, 2003,26:881-885.
  • 4Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbAlc level. Diabetes Care,2000,23 : 1830-1834.
  • 5Bastyr EJ 3rd, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc. IOEZ Study Group. Diabetes Care, 2000,23:1236-1241.
  • 6Riddle MC. Evening insulin strategy. Diabetes Care, 1990,13:676-686.
  • 7Weaver ML, Orwig BA, Rodriguez LC, et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos, 2001,29 (4 Pt 1 ) :415-421.
  • 8Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion : comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care, 2001,24:983-988.
  • 9Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus mefformin. Diabetes Care, 2005,28:2093-2099.
  • 10Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care, 2000,23:1660-1665.

共引文献1

同被引文献8

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部